Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.
Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.
Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.